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LETTERS to the EDITOR 
Immunohistochemical detection of
papillomavirus antigens in Kaposi’s sarcoma
SIR,-In this week’s issue (p 515) some of us, with other
colleagues, in New York, report molecular biological data indicating
a possible relation between human papillomavirus (HPV) and
Kaposi’s sarcoma (KS). Because epithelial cells seem to be the
dominant source for replication of HPV and productive infection in
the skin,’ we decided to examine biopsy specimens from patients
with cutaneous KS immunohistochemically, to see if keratinocytes
express HPV-related antigen (PRA).
From reviewing paraffin-embedded archival KS tissue 11 skin
biopsies from nine AIDS patients were immunostained, as were 6
skin samples from four elderly patients with classic KS and 3 from a
chronic renal failure patient who had received a kidney transplant.
The antiserum (Dako Corp, Santa Barbara, Califomia)2 was used at
1 in 500 dilution in combination with avidin-biotin peroxidase
staining, following blocking of endogeneous peroxidase activity,
with 3-amino-9-ethylcarbazole as the chromogen.3 In no specimen
was any epidermal cell (keratinocyte or Langerhans’) PRA positive
and no keratinocytes in KS displayed koilocytotic changes,
multinucleation, or viral inclusions. (In both vulvar condyloma and
cutaneous verruca, the same antibody only reacted with the nuclei of
koilocytotic cells in the upper epithelial layers, and not with any
dermal cells.) However, beneath the basement membrane zone,
dermal dendrocytes in both perilesional tissue and within the KS
lesion itself (fig 1) were stained positively in 14 (70%) of the 20 KS
lesions (8/11 AIDS KS, 4/6 classic KS, 2/3 transplant-associated
KS). At least two different lots of antisera against HPV were tested
(with equivalent results), no staining was seen when normal rabbit
serum was used as control or if the primary antibody was omitted;
and 3 biopsies of skin from AIDS patients with dermatitis were also
negative (both epidermis and dennis). While 1 AIDS-related
psoriasis specimen was negative a study of 10 additional non-
AIDS-related psoriatic plaques revealed that 6 had PRA
immunoreactive dermal dendritic cells but no epidermal positivity.
This suggests that there may be some situations in which dermal
dendritic cells express a cross-reactive protein not related to HPV
(unless HPV has a role in psoriasis).
We did two other experiments. We used a different monoclonal
antibody diluted 1 in 5000 (MAB 837; Chemicon International,
Temecula, California) to detect HPV proteins (HPV 1, 6, 11, 16,18,
and 31) on the same set of tissues. Except for the condyloma and
verruca, which had positive nuclear staining of epidermal
koilocytotic keratinocytes, all the KS and psoriatic specimens were
uniformly non-reactive in both epidermal and dermal
compartments. We also used a polyclonal rabbit anti-HPV-16-
specific antibody to the early region protein, E7 (provided by Dr
Douglas Lowy and Dr John Shiller, National Institutes of Health).
This antibody was used at a 1 in 1000 dilution with 3,3-
diaminobenzidine as chromagen and non-immune rabbit serum as
negative control. A KS lesion found to contain HPV-16 by
polymerase chain reaction (PCR) revealed positive intranuclear
staining of only the dermal spindle-shaped cells, whereas KS lesions
that were negative by PCR had no intranuclear staining in dermis or
epidermis (fig 2). The HPV-16-specific E7 antibody may be a more
specific marker than the other commercially available antibodies,
which detect capsid or late-appearing HPV gene products.
The striking PRA immunoreactivity of dermal dendrocytes in
these KS specimens was unexpected. The lack of epidermal
reactivity is also very surprising in the light of current
understanding of the pathophysiology of cutaneous HPV
infection.’ Confirmatory studies with molecular probes are in
progress. Although the positive immunostaining results, especially
those in non-AIDS-related psoriasis, demand DNA/RNA studies,
the uniformly negative epidermal reactivity in AIDS-related
specimens suggests that keratinocytes are not the site of productive
infection in these patients. It should be noted that transgenic mice
containing bovine papillomavirus genome develop dermal tumours
with prominent collections of spindle-shaped cells resembling
dermatofibromas.1 We demonstrated previously that human
dermatofibromas and KS lesions share histological features,
including increased collections of dermal dendrocytes.5
The aetiology and pathogenesis of KS remain a puzzle. The cell
of origin used to be thought of as the endothelial cel!6 but a relation
between cultured KS cells and dermal dendrocytes (a subset of
bone-marrow-derived monocyte/macrophages) has also been
considered.7 Dermal dendritic cells were prominent constituents of
the multicellular population observed in early KS5.7 and
unpublished studies of KS cell lines containing HPV DNA
sequences revealed that they expressed monocyte/macrophage but
not endothelial cell markers. Mahoney et al8 have demonstrated
HIV transcripts co-localising to dermal dendrocytes in three of
eight HIV-infected patients. However, there is epidemiological
evidence9’o that some sexually transmitted infectious agent other
than HIV may have a critical role in KS. Much more work is needed
to find out if the immunoreactivity reported here is recognising a
known strain of HPV or whether a novel non-epidermotropic strain ,
is involved in KS (or, indeed, an entirely different virus with a
cross-reactive capsid protein); and the possibility of endogenously
derived non-virus-associated cross-reactive proteins also deserves
Fig 1-Cutaneous KS lesion with prominent PRA
immunoreactive dermal dendritic cells in both angiocentric
and interstitial pattern.
Immunoperoxidase staining with red chromogen reaction product,
counterstained with haematoxylin, x 60.
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Fig 2-Cutaneous KS lesions examined by PCR and concomitant immunoreactivity for HPV-16-specific E7 protein.
Left strong nuclear immunoreactivity in dermal spindle-shaped cells from PCR-positive case (brown chronogen reaction product), x 200.
Right. absence of immunoreactivity in PCR-negative case, x 200
attention. Nonetheless, this letter and the article in this issue will, we
hope, prompt colleagues to consider papillomaviruses as possible
KS agents.
Dr J. T. Headington kindly reviewed slides and the text.
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Thalidomide for systemic lupus
erythematosus
SiR,&mdash;Treatment for systemic lupus erythematosus (SLE) is
largely symptomatic, with antimalarials, glucocorticoids, and
immunosuppressive drugs.’ Thalidomide has proved successful in
the treatment of chronic discoid lupus erythematosus (CDLE),2
antimalarial-resistant CDLE,3 subacute cutaneous lupus
erythematosus,4 and lupus erythematosus profundus.5 However,
thalidomide treatment of SLE has not yet been investigated in
detail.’ We report 3 patients with SLE, confirmed according to the
American Rheumatism Association 1982 criteria.
Patient 1-A 30-year-old woman had progressive acute SLE for
6 years (onset 1985) with multivisceral features-cutaneous,
articular, muscular, and neurological (severe polyneuropathy of the
lower limbs)&mdash;and impure renal nephrotic syndrome with
segmental and focal glomerulonephritis, pancytopenia, and
Raynaud’s syndrome. Immunological screening showed positive
antinuclear antibodies (ANA), anti-DNA-antibodies (titre 1/280),
anti-smooth muscle (SM) antibodies, and hypocomplementaemia.
Various treatments were instituted successively: corticosteroid (per
os or bolus injection) with corticodependence (25 mg per day),
cyclophosphamide, plasmapheresis, and cyclosporin. She had
severe infectious episodes with renal deterioration with these
treatments. 3! years after onset of SLE (July, 1988) thalidomide
(100 mg daily) combined with glucocorticoids (40 mg daily) were
instituted. Tolerance of this treatment was adequate with no
side-effects. Clinical improvement, with appreciably reduced skin
and articular features and without neuropathological deterioration,
led to a progressive decrease in glucocorticoid dose. Thalidomide
therapy was maintained for 2 years at daily doses of 25-100 mg. No
changes in immunological indices (ANA, anti-DNA antibodies,
and complement) were seen. The patient has since been kept on
maintenance corticosteroid therapy.
Patient 2-A 27-year-old woman had SLE for 5 years (onset
1986) with skin lesions and articular features (but no other visceral
symptoms) and immunological disorders: ANA (1/640), anti-DNA
antibodies, and anti-SM antibodies. Initial treatment with synthetic
antimalarials failed, and thalidomide (200 mg daily) was begun in
March, 1988. Cutaneous features almost completely disappeared
after 3 months of treatment and articular symptoms decreased
slightly. After 6 months on thalidomide she had serious drowsiness,
despite a reduction in dose. Treatment was stopped in November,
1988, which led to recrudescence of skin and articular features.
General corticosteroid therapy was then instituted with adequate
therapeutic response.
Patient 3-A 26-year-old woman had SLE for 5 years (onset
1986) with skin lesions and articular features and immunological
disorders: ANA (1/1024), anti-SM antibodies, and
hypocomplementaemia. General corticosteroid therapy after initial
